Interviews

Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.

Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br /> &nbsp;

Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.

David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.

Andre Goy, MD, discusses the agents he finds most promising for the treatment of patients with mantle cell lymphoma.

Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.

Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.

Natalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.

Arlene O. Siefker-Radtke, MD, discusses the data seen with sacituzumab govitecan, an antibody-drug conjugate that targets TROP-2, which is expressed frequently in urothelial cancer cells.

Shilpa Gupta, MD, discusses the progress over the last few years in bladder cancer.

Sangmin Lee, MD, discusses a potential way to overcome resistance to venetoclax in acute myeloid leukemia.

Gareth Morgan, MD, discusses where he sees the field headed for the treatment of patients with multiple myeloma.

Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses how common RET alterations are in thyroid cancers.

Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.

Jean-Jacques Kiladjian, MD, PhD, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera still remained on treatment with ruxolitinib.

Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.

Victor A. Chow, MD, discusses the next steps for chimeric antigen receptor T-cell therapy in patients with B-cell lymphomas.

Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.

Brian T. Hill, MD, PhD, discusses the safety findings from the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19, axi-cel) in patients with diffuse large B-cell lymphoma.

Josep M. Llovet, MD, PhD, discussed the available treatment options for patients with hepatocellular carcinoma.

<br /> &#8203;Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.

Jame Abraham, MD, discusses the key takeaways from the phase Ib study of trastuzumab emtansine in combination with neratinib in patients with HER2-positive breast cancer.

Krish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.

John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.

Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.

Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.

Arjun V. Balar, MD, discusses a few approaches for incorporating immunotherapy treatments into the frontline for patients with bladder cancer.

Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.

Ezra Cohen, MD, discusses the advancing field of immunotherapy in the treatment landscape for patients with head and neck cancers. Prior to the use of PD-1/PD-L1 blockades, which have been the most tested immunotherapy in this setting, there were little treatment options.

Manish A. Shah, MD, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma.